5-Azacytidine Promotes an Inhibitory T-Cell Phenotype and Impairs Immune Mediated Antileukemic Activity
Figure 7
In vivo effects of 5-Azacytidine in the treatment after alloSCT. (a) CD4+ and CD8+ T-cells were measured in the peripheral blood of three different patients during their treatment with 5-Aza. Data is shown as mean with SD and depicted values are baseline (before the first application of 5-Aza) and at the end of the 2 cycles (after treatment). (b) CD3+ T-cells were analyzed for the expression of HLA-DR by flow cytometry as long-term activation marker during treatment with 5-Aza. Time points are identical with those in (a). Data were shown as median with SD. (c) Cells expressing CD4+/CD25hi/CD127lo were considered to be Treg cells. Tregs were measured in weekly intervals for both cycles. Data were shown as mean with SD. ( shows the time point of 5 days of 5-Aza as treatment). (). (d) Naïve T-cells were classified by the expression of CD3+/CD4+ or CD8+/CD45RA+. In contrast, cells expressing CD45RO were considered to be memory T-cells. Data is shown as mean with SD and depicted values are baseline (before the first application of 5-Aza) and at the end of the 2 cycles (after treatment).
